Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis, Oncology, and Anti-Aging Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL-11 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-11 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View IL-11 Products |
| Receptor ECD | IL-11Rα ECD-Fc Fusion Protein Sequence-verified extracellular domain. Theoretical MW confirmed by mass spec. HEK293 expressed. |
View IL-11Rα Products |
| Co-Receptor | gp130 (IL6ST) ECD Protein Common beta subunit for IL-6 family selectivity counter-screening. |
View gp130 Products |
| Mutant Panel | IL-11 Alanine Scanning Mutants Structure-function mapping for epitope identification. Endotoxin controlled. |
View IL-11 Products |
| Gene Delivery | IL-11Rα Lentivirus Premade Particles Full-length ORF for stable Ba/F3 reporter cell line construction. |
View IL-11Rα Products |
| Benchmark Ab | Anti-IL-11 Neutralizing Reference Antibody Recombinant positive control for blocking assay validation. Sequence based on clinical candidate (BI 765423). |
View IL-11 Products |
| Validator | IL-11 siRNA Set For knockdown specificity verification and target validation. |
View IL-11 Products |
| Related Target A | IL-11RA (Full-length) Primary receptor for IL-11 complex formation. |
View IL-11RA Products |
| Related Target B | IL-6ST (gp130) Shared signaling co-receptor for IL-6 family cytokines. |
View IL-6ST Products |
| Related Target C | IL-6 Primary comparator for gp130 shared receptor selectivity studies. |
View IL-6 Products |
| Related Target D | OSM (Oncostatin M) gp130 family member for extended off-target screening. |
View OSM Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| IL-6 Family Selectivity (Shared gp130) | Panel of IL-6 family cytokines (IL-11, IL-6, OSM, LIF, CT-1) with >95% purity. Human/Mouse/Cyno orthologs available for cross-species epitope mapping. |
| IL-11Rα Binding Affinity & Receptor Complex | HEK293-expressed IL-11Rα ECD-Fc with native glycosylation. Low endotoxin (<0.01EU/ug) for high-sensitivity SPR/BLI. Also high-purity gp130 for competitive binding assays. |
| Functional Blocking Validation | STAT3 Reporter Cell Lines compatible with lentiviral transduction systems. Controlled IL-11 protein for dose-response curves. |
| Epitope Mapping | Systematic alanine scanning mutant library covering receptor-binding interfaces. Sequence verified. |
| Cross-Species Translation | Human, Mouse, and Cynomolgus IL-11 proteins with matched specifications for preclinical immunogenicity assessment. |
| Positive Control Standardization | Clinical Benchmark Antibodies (biosimilars based on BI 765423 and others) included for neutralization assay standardization. |
Live IL-11 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials
- Latest Fibrosis & Aging Research
- Recent Patent Filings (Antibody Inhibitors)
Global Clinical Landscape & Future Outlook
The therapeutic paradigm for IL-11 has shifted decisively from agonist strategies (thrombopoiesis induction) to antagonist modalities targeting fibrosis, oncology, and anti-aging. Originally overshadowed by other IL-6 family members, IL-11 is now recognized as a primary driver of fibro-inflammatory diseases across multiple organs (lung, liver, kidney, heart). Landmark preclinical studies demonstrating that IL-11 blockade extends healthspan and lifespan have accelerated interest. As first-generation monoclonal antibodies targeting either IL-11 (e.g., BI 765423 by Boehringer Ingelheim/Enleofen) or its receptor IL-11Rα (e.g., LASN01 by Lassen Therapeutics) enter Phase I trials for IPF and NASH, the next wave of R&D is exploring bispecific formats (IL-11/IL-11Rα), receptor-Fc fusions (traps), and siRNA/antisense strategies, alongside tissue-specific delivery systems for hepatic, pulmonary, and age-related pathologies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (anti-IL-11 or anti-IL-11Rα) | Bayer, Roche, Boehringer Ingelheim (Enleofen), Lassen Therapeutics | IPF, Colorectal Cancer, Liver Fibrosis, NASH, Anti-aging | gp130 Family Selectivity Panel; Receptor Internalization Assay; Need purified IL-11, IL-11Rα, gp130, and IL-6/OSM/LIF controls. |
| siRNA/Antisense | Various Academic/Preclinical | Organ-specific Fibrosis | Knockdown Validation; Need Sequence Verified siRNA and purified antigens for efficacy assessment. |
| Bispecific (IL-11/IL-11Rα) | Emerging Biotech, Early Stage Innovators | Metastatic Disease, Complex Fibro-inflammatory Disease | Heterodimer Validation; Epitope Binning; Need both ligand and receptor proteins in various formats. |
| Receptor-Fc Fusion (Trap) | Preclinical | Systemic Fibrosis | Competitive Binding Assay; Need high-affinity IL-11Rα and gp130 proteins. |